Lisdexamfetamine

Limits on what this shows

• Key negative/null findings: No clinical (human, therapeutic-dose) or lisdexamfetamine-specific preclinical study measuring mitochondrial function directly was located.
• At-risk subgroups: Theoretical only; none clinically defined.

Regulatory status

Not addressed in FDA labeling.

Population evidence

None at Tier A or Tier B for lisdexamfetamine itself. Repeated PubMed searches combining "lisdexamfetamine" with "mitochondrial," and with "ATP," "mitochondrial," and "oxidative stress" together, returned clean zero-result pages (see access note); a further attempt to confirm via Europe PMC was rate-limited and not completed. Tier C, active-metabolite extrapolation only: Cunha-Oliveira T et al., PMID 16638611 (rat cortical neuron culture, amphetamine), and PMID 11198300 (dopaminergic neuron culture), both amphetamine/dextroamphetamine-specific, not lisdexamfetamine-specific, previously catalogued in this project's amphetamine/dextroamphetamine dossier.

Mechanism

Named at Tier C only: dopamine auto-oxidation and intracellular dopamine redistribution driving mitochondrial membrane depolarization and caspase-mediated toxicity in dextroamphetamine culture models. The renal apoptosis finding for lisdexamfetamine itself (PMID 39051179, above) is mechanistically adjacent, since the intrinsic apoptotic pathway is mitochondria-mediated, but that paper did not report a mitochondrial-specific endpoint (membrane potential, cytochrome c release, or biogenesis marker), so it is cited here as partial, indirect support, not a direct mitochondrial measurement.

Counter-evidence held on record

Because lisdexamfetamine is fully hydrolyzed to dextroamphetamine in blood before reaching most tissues, extrapolating the dextroamphetamine mitochondrial-culture findings to this drug is mechanistically reasonable but remains Tier C for lisdexamfetamine specifically, not Tier B; the cohort test in Step 4 was not met by any source naming lisdexamfetamine directly for this category. See Overlap map with Oxidative stress and ATP production.

Limits on what this shows

• Key negative/null findings: The renal study is itself a partial null result for oxidative stress specifically: despite measurable inflammation (myeloperoxidase, NAG activity) and apoptosis, the paper's own conclusion states antioxidant activity was not disrupted. This is quoted here because it is the more clinically cautious reading of that source, not folded into a claim of confirmed oxidative damage. No human clinical study measuring oxidative stress markers in lisdexamfetamine-treated ADHD or BED patients was located in this review.
• At-risk subgroups: Theoretical only, drawn from doses (10 to 30 mg/kg in adult rats; 11.3 mg/kg/day in peripubertal rats) that are supratherapeutic relative to labeled human oral dosing (roughly 0.5 to 1.2 mg/kg/day at typical 30 to 70 mg adult doses); none clinically defined in humans.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Tier B, animal, lisdexamfetamine dimesylate specifically. Macêdo DS et al., "Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania," Prog Neuropsychopharmacol Biol Psychiatry 2013, PMID 23333378: adult rats given LDX 10 and 30 mg/kg showed increased lipid peroxidation, reversed and prevented by lithium, alongside LDX-induced hyperlocomotion. Honório da Silva JV et al., "Lisdexamfetamine dimesylate-exposition in male rats during the peripubertal period impairs inflammatory mechanisms, antioxidant activity, and apoptosis process in kidneys of male pubertal rats," J Biochem Mol Toxicol 2024, PMID 39051179: male Wistar rats given LDX 11.3 mg/kg/day from postnatal day 25 to 65 showed increased renal cell death and reduced tubule diameter and elevated inflammatory markers (myeloperoxidase, NAG activity), while the renal antioxidant system itself was reported "working undisrupted." Eger GA et al., "Antioxidant effect of simvastatin throught oxidative imbalance caused by lisdexamfetamine dimesylate," 2016, PMID 26871491, and Kanazawa LKS et al., "Andrographolide blocks 50-kHz ultrasonic vocalizations, hyperlocomotion and oxidative stress in an animal model of mania," 2021, PMID 34058655, both replicate the LDX-induced oxidative-stress/hyperlocomotion mania paradigm using different candidate reversal agents; full abstracts for these two could not be retrieved this session (see access note), so their quantitative findings are not independently verified beyond the indexed titles.

Mechanism

Named for the mania-model studies: dextroamphetamine-driven dopaminergic/catecholaminergic hyperactivity drives lipid peroxidation, used deliberately as a validated rodent model of manic-phase oxidative stress. Named for the renal study: inflammatory infiltration and apoptotic signaling in proximal tubule tissue following chronic peripubertal exposure, with the antioxidant enzyme system specifically reported as not disrupted despite the inflammatory and apoptotic changes.

Counter-evidence held on record

The renal study's own finding that the antioxidant system was "working undisrupted" is a real counter-weight against reading this entry as confirmed oxidative depletion; it is presented here as a mixed, drug-specific finding (inflammation and apoptosis present, redox capacity preserved) rather than rounded up to a clean depletion signal. See Overlap map: this entry's mania-model sources partially overlap with the Mitochondrial burden entry's inferential reasoning. All quantitative findings here come from rodent doses well above labeled human therapeutic exposure or from a developmental-window exposure paradigm; do not present this as an established finding at prescribed adult or pediatric ADHD/BED dosing.

Limits on what this shows

• Key negative/null findings: None identified specific to lisdexamfetamine; the zero-result ferritin search is itself the main finding for this drug.
• At-risk subgroups: Children and adolescents with low-normal ferritin at treatment initiation; iron-deficient populations generally, by extrapolation from the stimulant-class literature.

Regulatory status

Not addressed in FDA labeling. No iron-related warning, monitoring requirement, or interaction is listed for VYVANSE.

Population evidence

A PubMed search for "lisdexamfetamine ferritin" returned "No results were found," a clean, confirmed zero, not a blocked or bot-checked page. The relevant iron/ferritin-response literature previously catalogued in this project's amphetamine/dextroamphetamine dossier (Calarge CA et al., PMID 21186968, "serum ferritin and amphetamine response in youth with ADHD") predates Vyvanse's broad adoption and, on the evidence available in this review, cannot be confirmed to have used lisdexamfetamine as the studied stimulant; it is therefore treated as Tier C, class/active-metabolite extrapolation, for lisdexamfetamine specifically, not carried forward at the amphetamine dossier's orange grade.

Mechanism

Named at Tier C: iron is an obligate cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, biologically consistent with iron/ferritin status modulating response to any dopaminergic stimulant, lisdexamfetamine included, but not confirmed as directly tested for this drug.

Counter-evidence held on record

Do not describe lisdexamfetamine as depleting iron; no source located here shows that in either direction for this drug specifically. Do not present this as an established response-predictor for Vyvanse; the underlying study's use of this specific drug is unconfirmed. This finding does not support routine iron supplementation in every patient on lisdexamfetamine; iron supplementation without a measured, low ferritin carries a real risk of iron overload (see Safety review).

Limits on what this shows

• Key negative/null findings: Targeted searches combining lisdexamfetamine with copper terms, singly and in combination with zinc/microbiome terms, returned no study isolating a lisdexamfetamine effect on copper from ADHD disease status itself.
• At-risk subgroups: None defined at the drug level. Presented as a disease-state context flag per Hard Rule 6 (confounding by indication presumed until excluded), applicable to the ADHD population broadly and not confirmed to extend to the BED population, which was not studied in either copper source.

Regulatory status

Not addressed in FDA labeling.

Population evidence

A combined PubMed search for "lisdexamfetamine copper zinc gut microbiome microbiota" and again for "lisdexamfetamine copper zinc gut microbiome" both returned clean "No results were found" pages. The ADHD-copper case-control literature previously catalogued in the amphetamine/dextroamphetamine dossier ("Serum zinc, copper, zinc-to-copper ratio, and other essential elements and minerals in children with ADHD," PMID 31869738; "Decreased Serum Cu/Zn SOD Associated with High Copper in Children with ADHD," PMID 23861627) did not confirm medication status of the studied children in either case, so it is Tier C class/disease-extrapolation for lisdexamfetamine, exactly as it was for amphetamine, not independently strengthened here.

Mechanism

Not lisdexamfetamine-specific and not stimulant-specific. The proposed mechanism in the source literature relates to ADHD pathophysiology itself (dopaminergic/noradrenergic dysregulation and its downstream trace-element correlates), not to any particular drug's pharmacology.

Counter-evidence held on record

Do not present this as lisdexamfetamine altering copper status. It is an ADHD-associated finding in the pediatric literature, unconfirmed to extend to adult BED patients, and present whether or not the person is medicated, based on the sources located here.

Limits on what this shows

• Key negative/null findings: No human ADHD- or BED-treatment microbiome study, and no lisdexamfetamine-specific animal microbiome study, was located in this review.
• At-risk subgroups: None clinically defined.

Regulatory status

Not addressed in FDA labeling.

Population evidence

None at Tier A or B for lisdexamfetamine; two independent combined PubMed searches ("lisdexamfetamine copper zinc gut microbiome microbiota" and "lisdexamfetamine copper zinc gut microbiome") both returned clean zero-result pages. Tier C only, via the amphetamine/dextroamphetamine dossier's mouse-model sources (PMID 31978078, PMID 40924818), which used amphetamine itself, not the lisdexamfetamine prodrug, and were not repeated with the prodrug molecule.

Mechanism

Named at Tier C only, for amphetamine: gut microbiome composition shift with a butyrate/epigenetic pathway modulating amphetamine's own behavioral effects. Not established for the intact lisdexamfetamine molecule, which is absorbed via an intestinal peptide-transporter-mediated route distinct from free-base amphetamine absorption; whether the prodrug itself, prior to blood-borne hydrolysis, has any direct gut-luminal or mucosal microbiome interaction was not addressed in any source located here.

Limits on what this shows

• Key negative/null findings: Population-level cardiovascular labeling shows only small mean increases in blood pressure (about 2 to 4 mmHg) and heart rate (about 3 to 6 bpm) at therapeutic dosing, arguing against a population-wide oxygen-delivery problem. The vasculopathy signal is a labeled class/case-level finding, not a general-population finding.
• At-risk subgroups: Patients with pre-existing Raynaud's phenomenon, connective tissue disease, or vasospastic tendency.

Regulatory status

Labeled warning in FDA prescribing information/DailyMed stating that "CNS stimulants, including VYVANSE, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon," with instruction to evaluate patients who develop digital changes and consider rheumatology referral.

Population evidence

Tier A: FDA/DailyMed labeling names VYVANSE specifically in this class warning. This mirrors the same warning carried in the Adderall label reviewed in the companion amphetamine/dextroamphetamine dossier in this series; here it is confirmed independently against the lisdexamfetamine-specific label text rather than assumed to carry over.

Mechanism

Named: alpha-adrenergic-mediated peripheral vasoconstriction from the active metabolite dextroamphetamine's catecholamine-releasing sympathomimetic action, reducing digital and limb blood flow and local tissue oxygen delivery in susceptible individuals.

Counter-evidence held on record

This is a bounded, labeled adverse-effect signal, not evidence that lisdexamfetamine impairs whole-body oxygen delivery in typical patients. Do not generalize to hemoglobin, hematocrit, or systemic arterial oxygenation, which are not implicated in the sources reviewed here.

Limits on what this shows

• Key negative/null findings: No direct ATP/ADP ratio, oxygen-consumption-rate, or ATP-synthase-activity study for lisdexamfetamine or dextroamphetamine at any dose was identified in this review.
• At-risk subgroups: None clinically defined.

Regulatory status

Not addressed in FDA labeling.

Population evidence

None at Tier A or B for lisdexamfetamine. A combined PubMed search for "lisdexamfetamine" with "ATP," "mitochondrial biogenesis," and "energy" returned a clean zero-result page. Tier C only, via the Mitochondrial burden entry's dextroamphetamine culture sources (PMID 16638611, PMID 11198300).

Mechanism

Named only at two removes: dextroamphetamine-induced mitochondrial membrane depolarization (Tier C for this drug) would be expected to impair oxidative-phosphorylation-based ATP synthesis, but ATP itself was not the endpoint measured in any source located for either lisdexamfetamine or dextroamphetamine.

Counter-evidence held on record

This entry should not be read as separate confirmation alongside Mitochondrial burden (Hard Rule 9, see Overlap map); it is carried at yellow only because a plausible, named mechanism exists, not because ATP synthesis was ever measured.